| Market Capitalization (Millions $) |
626 |
| Shares
Outstanding (Millions) |
95 |
| Employees |
113 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-131 |
| Cash Flow (TTM) (Millions $) |
-22 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Aura Biosciences Inc is a clinical-stage biotechnology company that focuses on developing and commercializing innovative cancer therapies. The company specializes in developing targeted therapies called viral nanoparticles, which are designed to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. These nanoparticles are engineered to selectively bind to cancer cells and are activated by light, resulting in the destruction of the tumor.
One of the company's lead candidates is AU-011, which is being investigated as a treatment for choroidal melanoma, a rare and aggressive eye cancer. AU-011 has shown promising clinical results in early-stage studies and is currently being evaluated in advanced clinical trials.
Aura Biosciences Inc aims to provide a more effective and targeted treatment approach for cancer patients, reducing side effects and improving the quality of life. By harnessing the power of viral nanoparticles, the company is advancing the field of precision medicine and working towards better outcomes for patients with various types of cancer.
Company Address: 80 Guest Street Boston 2135 MA
Company Phone Number: 500-8864 Stock Exchange / Ticker: NASDAQ AURA
|
1.03% 